Welcome to our dedicated page for Lifecore Biomedical SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Lifecore Biomedical, Inc. (NASDAQ: LFCR), a Delaware corporation based in Chaska, Minnesota that operates as a fully integrated CDMO focused on sterile injectable pharmaceuticals and injectable-grade hyaluronic acid. These regulatory documents offer detailed insight into how the company reports its operations, governance, and financial condition.
Through filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of Lifecore’s CDMO and HA manufacturing activities, risk factors, and management’s analysis of results. Current reports on Form 8-K highlight specific events, including financial results announcements, changes in independent registered public accounting firms, investor presentations used in discussions with analysts, and matters submitted to a stockholder vote at the annual meeting.
The definitive proxy statement on Form DEF 14A describes corporate governance topics such as director elections, auditor ratification, and advisory votes on executive compensation, as well as stock ownership and compensation discussion and analysis. Other filings may address compensation plans and incentive structures, including bonus plans tied to metrics like Adjusted EBITDA and total revenue, as described in the company’s disclosures.
On Stock Titan, these filings are updated from the SEC’s EDGAR system and can be paired with AI-powered summaries that help explain complex sections, highlight key changes, and clarify terminology. Users can quickly identify items related to financial performance, internal control matters, auditor changes, and stockholder voting outcomes without reading every page. For those interested in governance, accounting, or the details behind Lifecore’s CDMO and HA manufacturing business, this filings page serves as a structured entry point into the company’s official regulatory record.
Lifecore Biomedical, Inc. reported strong improvement for the seven‑month transition period ended December 31, 2025, with revenue of $75.5 million, up 20% from $63.0 million in the comparable 2024 period. Gross margin rose to 31% from 26%, while operating expenses fell to $24.4 million, a 31% reduction from $35.6 million. Net loss narrowed to $18.0 million from $30.6 million, and Adjusted EBITDA increased to $13.1 million from $2.6 million, with free cash flow of $3.6 million versus a prior use of $11.8 million. Lifecore ended the quarter with $38.9 million of liquidity, including $17.5 million of cash and $21.4 million of revolver availability.
For 2026, the company guides to revenue of $120–$125 million and a GAAP net loss of $(33.4)–$(28.9) million, compared with pro forma 2025 revenue of $141.4 million and a net loss of $(26.0) million. 2026 Adjusted EBITDA is projected at $20.5–$25.0 million versus pro forma 2025 Adjusted EBITDA of $30.1 million. The balance sheet shows total assets of $232.2 million and total liabilities of $198.1 million, with stockholders’ equity at $(14.2) million.
The capital structure includes Series A Redeemable Convertible Preferred Stock with an aggregate liquidation preference of $50.2 million as of June 29, 2026; holders may demand redemption from that date, and unpaid amounts accrue interest at 1.0% per month. Under Lifecore’s term loan with Alcon Research, LLC, interest is currently payable‑in‑kind, but starting in May 2026, 3% per year becomes payable in cash through maturity in May 2029, with the remaining 7% continuing as payable‑in‑kind. Management targets a 12% revenue CAGR from 2025–2029 and EBITDA margins above 25% over the mid‑term, supported by expanded capacity, new customer programs, and an ERP system launched in January 2026 intended to improve efficiency.
Lifecore Biomedical, Inc. is aligning its corporate calendar with the calendar year after previously changing its fiscal year to end on December 31 for the period from May 26, 2025 to December 31, 2025. The company also plans to align its Annual Meetings and proxy filings with typical calendar-year reporting practices.
The Board has set June 4, 2026 as the date of the 2026 Annual Meeting of Stockholders. Because this is more than 30 days earlier than the prior year’s October 29, 2025 meeting, shareholder proposals and director nominations must be received by March 16, 2026 and must meet all requirements under SEC rules, the company’s Bylaws, and Delaware law.
Lifecore Biomedical’s Chief Legal & Administration officer, Thomas D. Salus, was granted an equity award reported as 30,000 shares of common stock at a price of $0.00 per share. This represents a grant, award, or other acquisition rather than an open-market purchase.
Footnotes explain that the award consists of restricted stock units that convert into common stock of Lifecore Biomedical, Inc. on a 1-for-1 basis. These restricted stock units will vest on the third anniversary of the grant date. Following this award, Salus directly holds 270,978 shares.
BlackRock, Inc. has disclosed a passive ownership stake in Lifecore Biomedical, Inc., reporting beneficial ownership of 1,899,903 shares of common stock, representing 5.1% of the class as of 12/31/2025. BlackRock reports sole power to vote 1,876,400 of these shares and sole power to dispose of all 1,899,903 shares, with no shared voting or dispositive power.
The filing clarifies that the stake is held through certain BlackRock business units in the ordinary course of business and is not held for the purpose of changing or influencing control of Lifecore Biomedical. Various underlying clients and investors have rights to dividends or sale proceeds, but no single such person has more than five percent of Lifecore’s outstanding common shares.
Lifecore Biomedical, Inc. reported that its Compensation Committee approved and adopted a new Incentive Bonus Plan effective January 14, 2026. The plan covers executive officers and certain other employees chosen by the committee and provides for cash bonus payments based on achieving financial and other performance targets.
The committee has broad authority under the plan to select participants, set performance periods, choose and weight performance goals, determine bonus amounts, link payouts to the level of goal achievement, and adjust awards for unusual events such as acquisitions or divestitures. The full text of the Incentive Bonus Plan is filed as Exhibit 10.1 to the report.
Lifecore Biomedical, Inc. reported that, beginning on November 18, 2025, it intends to use an updated investor presentation in discussions with certain investors, analysts and other parties. The presentation, dated November 17, 2025, is provided as an exhibit and will also be available on the company’s investor relations website under events and presentations. The disclosure is made under Regulation FD to make the same information available to the broader market.
Lifecore Biomedical (LFCR) reported Q3 results for the calendar quarter ended September 30, 2025. Total revenues were $31,109 thousand, up from $24,705 thousand, driven by HA manufacturing $9,360 thousand and CDMO $21,749 thousand. Gross profit rose to $7,791 thousand from $5,387 thousand, and the operating loss improved to $3,067 thousand from $11,584 thousand.
Net loss was $9,991 thousand versus $16,230 thousand, with loss per share of $0.29. Cash and cash equivalents were $18,856 thousand. The company completed a capacity expansion expected to more than double aseptic capacity; depreciation is expected to increase by approximately $1,600 per year.
Alcon accounted for 38% of revenue and is also the term-loan lender. Related party term-loan principal was $179,562 thousand with an effective annual interest rate of 20.9%, and the company remained in compliance with covenants. Contract liabilities, current, were $7,214 thousand. Shares outstanding were 37,466,352 as of October 30, 2025. The company paid-in-kind preferred dividends of $874 thousand and recorded a stockholders’ equity deficit of $10,537 thousand.
Lifecore Biomedical (LFCR) furnished updates tied to its latest quarter. The company issued a press release announcing consolidated financial results for the three months ended September 30, 2025, furnished as Exhibit 99.1. It also made an investor presentation available on its website, furnished as Exhibit 99.2. The materials were provided on November 6, 2025 and are furnished, not filed, under the Exchange Act. Lifecore’s common stock trades on the NASDAQ Global Select Market under the symbol LFCR.
Lifecore Biomedical (LFCR) reported the results of its 2025 annual meeting. Stockholders elected nine directors: seven were elected by all stockholders voting together, and two were elected solely by holders of the Series A Convertible Preferred Stock. The director slate received strong support across nominees.
Stockholders also ratified KPMG LLP as independent auditor for the fiscal year ending December 31, 2025, with 35,663,643 votes for, 15,326 against, and 68,718 abstentions. In a non-binding advisory vote, executive compensation was approved with 24,642,130 votes for, 238,354 against, 80,394 abstentions, and 10,786,809 broker non-votes.
As of the September 2, 2025 record date, there were 37,436,784 shares of common stock outstanding and entitled to vote. Series A Preferred totaled 46,593 shares, which were entitled to elect two preferred directors and to vote on an as-converted basis representing the equivalent of 7,131,735 common shares on other items, subject to applicable limits.
Lifecore Biomedical, Inc. approved a new cash incentive plan, the CY 2025 Transition Period Bonus Plan, covering the approximately seven-month period from May 26, 2025 through December 31, 2025. This plan replaces a previously approved 2026 bonus plan following the company’s change in fiscal year-end to December 31.
Under the plan, each executive officer’s cash bonus opportunity is weighted 80% to company financial performance based on Adjusted EBITDA and total revenue, 10% to individual performance objectives, and 10% to four equally weighted company business goals. No bonus is earned unless minimum Adjusted EBITDA is achieved, and the bonus tied to financial goals is capped at 200% of the target opportunity.
At the target level, bonus opportunities for the transition period are set at 100% of base salary for President and CEO Paul Josephs, 60% for CFO Ryan D. Lake, and 50% for Chief Legal and Administration Officer Thomas D. Salus, with Mr. Salus receiving 125% of any bonus he earns under his employment agreement. All payments are subject to the company’s compensation recoupment (clawback) policy.